PolyMVA Survivors

Description

Palladium Lipoic Complex: “Energy to Get the Job Done ” Anti-Aging Medicine Therapeutics, Vol. 8 (2006) Senior Scientist & Clinical Research Administrator, Garnett McKeen Laboratory, Incorporated Professor of Biology and Chairman, St. Joseph ’s College, New York . Palladium Lipoic Acid Complex (PdLA) is the most active ingredient in a dietary supplement called POLY-MVA. In the palladium lipoic acid complex, the element palladium is covalently bound to the anti-oxidant alpha-lipoic acid. In addition to PdLA, the proprietary blend of POLY-MVA is formulated with minerals, vitamins and amino acids such as molybdenum, rhodium, ruthenium, thiamine, riboflavin, cyanocobalamin, acetyl cysteine, and formyl methionine (Garnett 1995, 1997, 1998). Dr. Merrill Garnett invented POLY-MVA. While Dr. Garnett was formally trained as a dentist, he has done substantial graduate work and research in biochemistry and electrochemistry over a period of 40 years. His inquiry and screening of thousands of organo-metallic compounds led to the discovery of the non-toxic POLY-MVA supplement. Basic science and anecdotal clinical data suggest POLY-MVA to have chemotherapeutic properties. Dr. Garnett believes that the regulation of charge transfer may form the basis for new methods of drug discovery and medical treatment. In this overview, we would like to address some of the frequently asked questions and misconceptions regarding POLY-MVA that we encounter during our scientific presentations. A number of people are under the impression that the supplement, POLY-MVA, is merely a cocktail of palladium, alpha-lipoic acid, thiamine, riboflavin, cyanocobalamin, formyl-methionine and acetyl-cysteine. This is not true. There is no free alpha-lipoic acid or free palladium in POLY-MVA. They are bound together (Garnett 1995, Krishnan and Garnett 2006). This compound was synthesized by Dr. Garnett to create a metallic bioorganic molecule that demonstrates enhanced fat and water-solubility. Furthermore, it is prepared in a unique fashion so it does not produce toxic products upon consumption. This is unlike many other chemotherapeutics, which breakdown, accumulate in tissue and eventually become toxic. o The formulation has undergone extensive toxicology study (Calvert Laboratories, Inc; Pharmakon USA, Incorporated). The toxicology was conducted both intravenously a nd orally with PdLA. Mice were administered doses of 5,000 mg/kg (a typical human dose is 20 mg/kg). No deaths or signs of organ damage occurred in the test animals. It was concluded that the LD50 of PdLA exceeds 5,000 mg/kg. The same independent lab conducted the Ames test and no mutagenic effects were observed. o While platinum and palladium share many chemical properties, it appears that platinum coordination complexes are carcinogenic and genotoxic. There is no evidence of any mutagenic property for palladium(Bunger et al. 1996). In a study examining human lymphocytes, platinum demonstrated significant genotoxicity, likely mediated by oxidative damage, compared to palladium (Migliore et al. 2002).

Products & services

Similar companies nearby